|Position||Trades||Duration||Win rate||Win/loss||Avg win||Avg loss||Return|
|Position||Trades||Duration||Win Rate||Win/Loss||Avg Win||Avg Loss||Return|
EASE OF MOVEMENT
Trading: BUY @ $1.805
Signal Strength: MEDIUM
Volatility indicators highlight potential moves of a stock which can either move sharply in the updwards or downwards direction. This indicator allows stocks to be compared on a level playing field to highlight high and low volatility. Normally, falling markets are more likely to be volatile than a rising markets due to the emotion that gets tied to trading. Use volatility indicators in conjunction with other indicators to reduce exposure to false moves.
Mesoblast (ASX:MSB) current price have moved upwards on low volume. Currently, the EOM is 0.278.
The Ease of Movement (EOM) is a technical momentum indicator that is used to illustrate the relationship between the rate of an assets price change and its volume. This indicator attempts to identify the amount of volume required to move prices. Generally a value greater than zero is an indication that the stock is being accumulated (bought) and negative values are used to signal increased selling pressure. A high positive value appears when prices move upward on low volume. Strong negative numbers indicate that price is moving downward on low volume.
Calculation: Ease of Movement (EOM):
1) Distance Moved = ((H + L)/2 - (Prior H + Prior L)/2);
2) Box Ratio = ((V/100 000 000)/(H - L));
3) 1-Period EMV = ((H + L)/2 - (Prior H + Prior L)/2) / ((V/100 000 000)/(H - L));
4) 14-Period Ease of Movement = 14-Period simple moving average of 1-period EMV
PROFILE: Mesoblast (MSB.AX)
Stock Exchange: ASX
Ticker Codes: | MSB.AX | ASX:MSB |
Mesoblast Limited develops cell-based medicines. The company has leveraged its proprietary technology platform based on mesenchymal lineage adult stem cells to establish a portfolio of late-stage product candidates. Its allogeneic cell product candidates target advanced stages of diseases with high and unmet medical needs, including cardiovascular conditions, immunologic and inflammatory conditions, orthopedic disorders, and oncology and hematology conditions. The company's products under the Phase III clinical trials include MPC-150-IM for chronic and end-stage heart failure; MPC-06-ID for chronic low back pain; and MSC-100-IV for acute graft versus host disease in children. It is also developing MPC-300-IV that is in Phase II clinical trials for the treatment of biologic refractory rheumatoid arthritis, and diabetic kidney diseases and type 2 diabetes. The company has a collaboration agreement with JCR Pharmaceuticals Co., Ltd. It has operations in the United States, Australia, Singapore, and Switzerland. Mesoblast Limited was founded in 2004 and is headquartered in Melbourne, Australia.
|SMN Structural Monitoring Systems||0.98||4.8||47,285||-1.24||BEARISH|
|PSQ Pacific Smiles||1.77||4.1||3,500||-0.03||BEARISH|
|SMX Sms Management & Technology||0.3||3.4||1,266||-0.02||BEARISH|
|BBN Baby Bunting||3.81||3||429,199||-0.06||BEARISH|